Biotech & AI drug discoverySTAT — Biotech

STAT+: Lilly's Jaypirca approved as first-line CLL therapy

According to STAT+, Eli Lilly's Jaypirca has won FDA approval as a first-line therapy for previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.

AI summary · generated only from source feed metadata; consult original

Source published2026-10-05T13:55:41+00:00

Published here2026-10-05T14:11:14+00:00

Original source

STAT — Biotech

Media report · consult original reporting

Read the original ↗https://www.statnews.com/2026/10/05/biotech-news-lilly-jaypirca-approved-as-first-line-cll-therapy/

Original headline

STAT+: Lilly’s Jaypirca approved as first-line CLL therapy

AI bilingual edit · consult original

Headlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.